Good Health Can’t Wait.

More documents

Recommendations

Info

Good Health Can’t Wait. Dr. Reddy’s Laboratories Limited NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.14: SHORT TERM LOANS AND ADVANCES PARTICULARS AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 Unsecured Considered good Balances with statutory / government authorities 7,150 6,960 Prepaid expenses 311 269 Other advances 1,196 1,058 Considered doubtful Other advances recoverable in cash or in kind or for value to be received 51 37 8,708 8,324 Less: Provision for doubtful loans and advances (51) (37) 8,657 8,287 2.15: OTHER ASSETS PARTICULARS AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 A) Non current assets In term deposit accounts (remaining maturity more than 12 months) 11 - 11 - B) Current assets Considered good Claims receivable 326 161 Interest accrued but not due on term deposits 92 175 Derivative financial asset 388 580 Receivables from subsidiary companies including step down subsidiaries: Reddy Antilles N.V., Netherlands 16 19 Dr. Reddy’s Bio-sciences Limited, India 69 70 Dr. Reddy’s Laboratories SA, Switzerland 29 332 Betapharm Arzneimittel GmbH, Germany - 534 Others 21 18 Other current assets 49 51 990 1,940 2.16: OTHER OPERATING REVENUE PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2014 Sale of spent chemicals 521 481 Scrap sales 270 135 Miscellaneous income 44 196 835 812 134
Standalone Financial Statements Annual Report 2014 - 15 NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.17: OTHER INCOME PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2014 Interest income On fixed deposits 403 870 On loans to subsidiaries 222 132 Others 316 20 Dividend from mutual fund units 26 - Dividend from subsidiaries (a) 79 12 Profit on sale of fixed assets, net - 28 Profit on sale of current investments, net 699 213 Foreign exchange gain, net 282 - Miscellaneous income 201 240 2,228 1,515 (a) Dividend received from Aurigene Discoveries Technologies Limited, India on equity shares during the year. Amount for previous year represents dividend received from Aurigene Discoveries Technologies Limited, India on preference shares. 2.18: CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND STOCK-IN-TRADE PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2014 Opening Work-in-progress 6,007 5,149 Finished goods 2,696 2,062 Stock-in-trade 940 9,643 726 7,937 Closing Work-in-progress 6,292 6,007 Finished goods 2,377 2,696 Stock-in-trade 1,263 9,932 940 9,643 (289) (1,706) 2.19: EMPLOYEE BENEFITS EXPENSE PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2014 Salaries, wages and bonus 12,257 11,775 Contribution to provident and other funds 728 663 Staff welfare expenses 1,405 1,289 Stock compensation expense, net 519 472 14,909 14,199 2.20: FINANCE COSTS PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2014 Interest on long term borrowings 190 124 Interest on other borrowings 457 930 Gain on interest rate swaps, net - (283) Changes in fair valuation of current investments (9) 12 638 783 135
Page 1 and 2:
ANNUAL REPORT 2014-15 Good Health C
Page 3 and 4:
Our Brand We are in the business of
Page 5 and 6:
Corporate Overview Annual Report 20
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Statutory Reports • Business Resp
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Statutory Reports • Management Di
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Statutory Reports • Corporate Gov
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Statutory Reports • Additional Sh
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86: Statutory Reports • Additional Sh
Page 87 and 88: Statutory Reports • Board’s Rep
Page 111 and 112: Standalone Financial Statements Ann
Page 135: Standalone Financial Statements Ann
Page 165 and 166: Consolidated Financial Statements A
Page 187 and 188:
Consolidated Financial Statements A
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Notice Annual Report 2014 - 15 NOTI
Page 229 and 230:
E-Voting Annual Report 2014 - 15 IN
Page 231:
Dr. Reddy’s Laboratories Limited
Page 235 and 236:
The future belongs, not to those wh
show all

Good Health Can’t Wait.

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?